APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)
APOLLO
A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer
1 other identifier
observational
862
1 country
19
Brief Summary
To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2007
Longer than P75 for all trials
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2007
CompletedFirst Submitted
Initial submission to the registry
August 30, 2007
CompletedFirst Posted
Study publicly available on registry
August 31, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2011
CompletedMay 20, 2011
May 1, 2011
3.9 years
August 30, 2007
May 19, 2011
Conditions
Keywords
Eligibility Criteria
Department of Surgery or Department of Hemato-oncology in 36 hospitals
You may qualify if:
- Provision of written informed consent
- Patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice
- Histologically or cytologically proven to be HR+(ER or PR +)
- Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline):
- Age \>= 50 years
- Age \< 50 years with amenorrhoea \> 12 months and an intact uterus
- FSH levels within postmenopausal range (over 30-40 IU/ml), or
- Having undergone a bilateral oophorectomy.
- No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
You may not qualify if:
- Recurrence of breast cancer
- Known hypersensitivity to aromatase inhibitor or to any of the excipients
- Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol
- Participation in a clinical study during the last 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (19)
Research Site
Cheonan-si, Chuncheongnam-do, South Korea
Research Site
Kangnung-si, Gangwon-do, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Jinju, Gyeongsangnam-do, South Korea
Research Site
Anyang-si, Gyunggi-do, South Korea
Reserach Site
Euijungbu-si, Gyunggi-do, South Korea
Research Site
Seongnam, Gyunggi-do, South Korea
Research Site
Suwon, Gyunggi-do, South Korea
Research Site
Iksan-si, Jeollabuk-do, South Korea
Research Site
Jeonju, Jeollabuk-do, South Korea
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Daejeon, South Korea
Research Site
Daejoen, South Korea
Research Site
Gwangju, South Korea
Research Site
Incheon, South Korea
Research Site
Seoul, South Korea
Research Site
Ulsan, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Joon Woo Bahn
AstraZeneca Korea
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 30, 2007
First Posted
August 31, 2007
Study Start
May 1, 2007
Primary Completion
April 1, 2011
Study Completion
April 1, 2011
Last Updated
May 20, 2011
Record last verified: 2011-05